Gaviscon Strawberry chewable tablets

Страна: Великобритания

Язык: английский

Источник: MHRA (Medicines & Healthcare Products Regulatory Agency)

Активный ингредиент:

Sodium alginate; Sodium bicarbonate; Calcium carbonate

Доступна с:

Reckitt Benckiser Healthcare (UK) Ltd

код АТС:

A02BX13

ИНН (Международная Имя):

Sodium alginate; Sodium bicarbonate; Calcium carbonate

дозировка:

250mg ; 133.5mg ; 80mg

Фармацевтическая форма:

Chewable tablet

Администрация маршрут:

Oral

класс:

No Controlled Drug Status

Тип рецепта:

Never Valid To Prescribe As A VMP

Обзор продуктов:

BNF: 01010201; GTIN: 5000158067592 5000158067608 5000158071315 5000158071339

Характеристики продукта

OBJECT 1
GAVISCON STRAWBERRY FLAVOUR TABLETS
Summary of Product Characteristics Updated 12-Dec-2014 | Reckitt
Benckiser Healthcare (UK) Ltd
1. Name of the medicinal product
Gaviscon Strawberry Flavour Tablets.
2. Qualitative and quantitative composition
Each tablet contains sodium alginate 250 mg, sodium hydrogen carbonate
133.5 mg, calcium carbonate 80 mg.
For excipients, see Section 6.1.
3. Pharmaceutical form
Chewable tablet. (Tablet)
Pale pink, circular, flat with bevelled edges with the odour and
flavour of strawberry.
4. Clinical particulars
4.1 Therapeutic indications
Treatment of symptoms of gastro-oesophageal reflux such as acid
regurgitation, heartburn and
indigestion, for example, following meals or during pregnancy.
4.2 Posology and method of administration
For oral administration, after being thoroughly chewed.
Adults and children 12 years and over: Two to four tablets after meals
and at bedtime.
Children under 12 years: Should be given only on medical advice.
Elderly: No dose modifications necessary for this age group.
4.3 Contraindications
This medicinal product is contraindicated in patients with known or
suspected hypersensitivity to the
active substances or to any of the excipients.
4.4 Special warnings and precautions for use
If symptoms do not improve after seven days, the clinical situation
should be reviewed.
The sodium content of a four-tablet dose is 246 mg (10.6 mmol). This
should be taken into account when
a highly restricted salt diet is recommended. e.g. in some cases of
congestive cardiac failure and renal
impairment.
Each four-tablet dose contains 320 mg (3.2 mmol) of calcium carbonate.
Care needs to be taken in
treating patients with hypercalcaemia, nephrocalcinosis and recurrent
calcium containing renal calculi.
Due to its aspartame content this product should not be given to
patients with phenylketonuria.
4.5 Interaction with other medicinal products and other forms of
interaction
A time-interval of 2 hours should be considered between Gaviscon
intake and the administration of oth